Clinical Trials Logo

Filter by:
NCT ID: NCT06345521 Recruiting - Heart Failure Clinical Trials

Etablishment of Follow-up System and End-Stage Heart Registration Platform for Pediatric Heart Failure

Start date: January 1, 2022
Phase:
Study type: Observational

Establish a follow-up management system for pediatric heart failure and a registration platform for end-stage heart failure

NCT ID: NCT06345365 Recruiting - Clinical trials for Acute Myeloid Leukaemia

MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)

Start date: January 18, 2024
Phase: Phase 3
Study type: Interventional

Investigator proposed to apply the new dosage form of mitoxantrone hydrochloride liposomes to the clinical treatment of AML, while combining with cytarabine and azacitidine to form the MA+AZA treatment regimen(Mitoxantrone liposome +Ara-Cytarabine+Azacitidine), which would provide an optimal induction treatment regimen for patients with primary AML by comparing with the traditional chemotherapy regimen, DA+AZA (Daunorubicin+Ara-Cytarabine+Azacitidine).

NCT ID: NCT06345300 Recruiting - Clinical trials for Borderline Resectable Pancreatic Cancer

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Start date: March 10, 2024
Phase: Phase 2
Study type: Interventional

The aim of this study is to assess the efficacy and safety of Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab for patients with borderline resectable pancreatic cancer

NCT ID: NCT06345287 Recruiting - Clinical trials for Head and Neck Cancer

Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC

Start date: January 1, 2024
Phase: Phase 2
Study type: Interventional

The aim of this study is to develop an adaptive radiation therapy plan for locally advanced head and neck squamous cell carcinoma receiving induction therapy containing immunotherapy and chemotherapy. The therapy plan is based on clinical remission, in order to reduce treatment-related toxic side effects without sacrificing clinical efficacy and improve the quality of life of patients.

NCT ID: NCT06345131 Recruiting - Surgical Patients Clinical Trials

Clinical Research Plan for the Safety and Accuracy of Ultrasound-guided Radial Artery Puncture Catheterization

Start date: July 1, 2023
Phase: N/A
Study type: Interventional

By observing the anatomical relationship and influencing factors of the radial artery through ultrasound, the optimal puncture location is selected, and puncture catheterization is guided to reduce the number of punctures, reduce complications, and improve safety and accuracy.

NCT ID: NCT06344962 Recruiting - Clinical trials for Suture, Complication

Clinical Effects of Absorbable and Non-absorbable Suture in Bronchial Sleeve Resection

Start date: February 28, 2023
Phase: N/A
Study type: Interventional

Bronchial sleeve resection is performed as an alternative to pneumonectomy for lung cancer patients with centrally located lesions and limited cardiopulmonary reserve. Intraoperative bronchial anastomosis is very complex and difficult, mainly due to the difficulty of suturing and knotting in limited space. There are currently few studies comparing the clinical effects of absorbable and non-absorbable suture in bronchial sleeve resection. So the investigator wants to conduct a prospective study, trying to figure out this problem.

NCT ID: NCT06344845 Recruiting - Clinical trials for Neurodegenerative Diseases

Clinical Study of [18F] PM-PBB3 PET Imaging of Tau Protein in Neurodegenerative Diseases

Start date: November 1, 2022
Phase: N/A
Study type: Interventional

In terms of the diagnostic technology of brain neurodegenerative diseases, the injection of positron tracers into the human body, so that it can combine with the corresponding protein, and show its distribution through PET imaging is a mature technology in the industry. At present, several research groups around the world are working on the development and clinical efficacy evaluation of their respective tau imaging agent compounds.This clinical research project intends to display the abnormal changes of tau protein in living brain through [18F]PM-PBB3 PET imaging, which is a second-generation tracer further optimized on the basis of [11C]PBB3, and has the advantages of closer binding to tau protein entanglement and less non-specific binding than similar imaging agents. Better image quality and a wider range of clinical applications.

NCT ID: NCT06344793 Recruiting - Breast Cancer Clinical Trials

Initial CDK 4/6 Inhibitor Plus Endocrine Therapy Versus Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

Start date: May 20, 2023
Phase:
Study type: Observational

A multi-center, real world study to evaluate the clinical outcomes between initial CDK 4/6 Inhibitor plus endocrine therapy and initial chemotherapy in HR positive, HER2 negative unresectable or metastatic breast cancer.

NCT ID: NCT06344780 Recruiting - Breast Cancer Clinical Trials

Abemaciclib, Palbociclib or Dalpiciclib Combined With Endocrine Therapy as First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

Start date: May 20, 2023
Phase:
Study type: Observational

A multi-center, real world study to evaluate the clinical outcomes and safety of Abemaciclib, Palbociclib or Dalpiciclib combined with endocrine therapy as first-line treatment in HR Positive, HER2 Negative unresectable or metastatic Breast Cancer.

NCT ID: NCT06344403 Recruiting - Acute Pain Clinical Trials

Clinical Efficacy and Safety of Tender Point Infiltration (TPI) for Acute and Subacute Zoster Associated Pain

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

Herpes zoster (HZ) is a skin infection disease which cause severe zoster-associated pain (ZAP) along sensory nerve in the corresponding segment. Evidence for the efficacy of existing local therapies for acute/subacute ZAP is limited. The hypothesis is that patients with acute/subacute ZAP treated with TPIs with local anesthetic and steroids under the basis of standard treatment will show better clinical outcomes compared with subjects treated with standard antiviral medicine treatment only.